Results 121 to 130 of about 25,852 (233)
The study aimed to compare the clinical outcomes of dual antiplatelet therapy (DAPT) vs. single antiplatelet therapy (SAPT) in branch atheromatous disease (BAD)‐related stroke. DAPT was safe but not statistically superior to SAPT for excellent functional outcome; however, its numerical trend toward benefit warrants further investigation.
Haizhou Hu +10 more
wiley +1 more source
Although patients with acute coronary syndrome supported by veno‐arterial extracorporeal membrane oxygenation (VA‐ECMO) have a high risk of thrombosis and bleeding, antiplatelet pharmacology in this setting is not well defined. This prospective observational study investigated the population pharmacokinetics of ticagrelor and its active metabolite AR ...
Soyoung Kang +9 more
wiley +1 more source
Early stent thrombosis (EST) (≤ 30 days after stent implantation) is a relatively rare but deleterious complication of percutaneous coronary intervention (PCI). Administration of newer P2Y12 inhibitors (prasugrel and ticagrelor) combined with aspirin has
Elad Asher +12 more
doaj +1 more source
Abstract Background The Veterans Health Administration (VA) cares for more than one million hospitalized Veterans each year. There is limited knowledge on how hospital medicine care in VA facilities compares with non‐VA hospitals in terms of the Institute of Medicine domains of healthcare access, patient experience, quality, clinical outcomes, and cost.
Paul G. Shekelle +4 more
wiley +1 more source
In the oxygen‐induced retinopathy (OIR) mouse model, two distinct microglial subpopulations play opposing roles: highly glycolytic microglia (HGM) promote neovascular formation via Pkm2, while Mrc1/CD206‐positive phagocytosis‐associated microglia (PAM) facilitate its regression.
Yuan Ma +20 more
wiley +1 more source
Beyond Hemostasis: Platelet Biomarkers and Vascular‐Immune Crosstalk in Dengue
Several biomarkers are associated with platelet activation during dengue virus (DENV) infection. These include serum markers (AST, ALT, ferritin), platelet surface or secreted molecules (P‐selectin, PF4, RANTES, VEGF‐A, CD40L, TREM‐1, TLT‐1), immune and endothelial markers (TREM‐1, Ang‐1, Ang‐2), and viral components such as DENV EIII.
Amanda Beatriz Adriano da Silva‐Alencar +6 more
wiley +1 more source
BackgroundWe aimed to clarify the association between intraoperative P2Y12 inhibitor administration during EVT and clinical outcomes in patients with anterior circulation TO stroke.MethodsAmong consecutive patients with acute ischemic stroke (AIS ...
Takeshi Yoshimoto +31 more
doaj +1 more source
Response variability to P2Y12 receptor inhibitors: expectations and reality.
P2Y12 inhibitors are widely used in patients with acute coronary syndromes and in the secondary prevention of thrombotic events in vascular diseases. Within the past few years, several pharmacological, genetic, and clinical limitations of the second-generation thienopyridine clopidogrel have raised major concerns. High on-treatment platelet reactivity,
Siller-Matula, Jolanta M +6 more
openaire +2 more sources
Die Rolle des P2Y12-Rezeptors in adipozytärem Gewebe [PDF]
In dieser Studie konnte gezeigt werden, dass der P2Y12-Rezeptor sowohl in ausdifferenzierten murinen als auch in humanen braunen und weißen Adipozyten exprimiert wird. Die Expression ließ sich sowohl durch Ernährung als auch durch die Umgebungstemperatur
Bienert, Simon
core
The 2023 ESC guidelines changed previously recommended a strategy of early treatment in patients with STEMI. Pre-treatment with a P2Y12 receptor inhibitor may be considered in patients undergoing a primary PCI strategy (Class IIb, Level of evidence B ...
Jacek Kubica +31 more
doaj +1 more source

